Dr Nicholas van As is Medical Director of The Royal Marsden, Consultant Clinical Oncologist in the Urology Unit, and a Reader at the Institute of Cancer Research.
Dr van As' main research interests are in stereotactic and image-guided radiotherapy, treatment of oligometastaic disease, risk prediction in early prostate cancer, and functional magnetic resonance imaging. He has published numerous papers on these subjects and delivered presentations at international meetings.
Dr van As is clinical lead for stereotactic body radiotherapy (SBRT) at The Royal Marsden, national clinical lead for NHS England's evaluation programme for SBRT. He is Chair of the UK SBRT Consortium. He leads a number of clinical trials, most notably he is chief investigator for the international clinical trial PACE, comparing SBRT to image-guided radiotherapy and surgery for treating localised prostate cancer.
Rebecca M. Howell, PhD, is a tenured Associate Professor at The University of Texas MD Anderson Cancer Center and a Fellow of the American Association of Physicists in Medicine (AAPM). She received her MS (2001) and PhD (2005) from the University of Texas Health Science Center San Antonio.
Dr Howell is Director of the Late Effects group at MD Anderson, which does retrospective dose reconstructions for numerous late effects studies for several large national and international cohorts including Childhood Cancer Survivor Study, St. Jude Life, Adult Life after Childhood Cancer in Scandinavia, and the Late Effects of Childhood Cancer task force of the Dutch Childhood Oncology Group. She is certified by the American Board of Radiology has more than 15 years of clinical experience, has published 60 peer-reviewed papers and is/has been a Principal and Co-investigator on several extramurally funded research grants and service agreements. Her research focuses on out-of-field dose and late effects of radiation therapy and she is recognized for her expertise in neutron dosimetry for both photon and proton therapy.
Dr Hien Le is a Royal Adelaide Hospital Radiation Oncologist with clinical interests in the application of innovative and emerging cancer technologies. He is also a Senior Research Fellow at the University of South Australia.
Dr Le received the Royal Australian and New Zealand College of Radiologists Windeyer Fellowship award in 2011 and with this spent a year at Mount Vernon Cancer Centre (UK) learning the techniques involved in Cyberknife radiation and MRI based image guided brachytherapy. In 2013, he received the College Thomas Baker award, completing an observership at the Massachusetts General Hospital (US) where he learned the applications of spread out Bragg peak and intensity modulated proton therapy.
Additionally, Dr Le is the local investigator on a number of Trans Tasman Radiation Oncology Group trials, local clinical trials and a member of the College Economics and Workforce committee.
Dr. Sofocleous is a professor of Radiology at Weill-Cornell Medical College of Cornell University, practicing interventional oncology at Memorial Sloan Kettering Cancer Center (MSKCC) in New York city since 2002. He is a world-renowned interventional oncologist a founding member and one of the directors at large of the Society of Interventional Oncology (SIO). He was the chair of the 2016 World Conference of Interventional Oncology (WCIO) and he serves as the international liaison of the annual meeting committee of the Society of interventional Radiology (SIR). He is a fellow of the SIR and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
His work on interventional oncology covers a wide range of image-guided procedures. Dr. Sofocleous is an opinion leader and worldwide expert on image guided therapies for metastatic disease especially colorectal cancer hepatic and pulmonary metastases. His dedication in research and promotion of knowledge through medical investigation have resulted in over 151 peer-reviewed publications and a scopus author citation index of over 4450 as of December 31, 2018. His contributions in the field of interventional oncology have been recognized nationally and internationally as indicated through the numerous invited lectures that he has delivered throughout the world, as well as his leadership roles in the Society of Interventional Radiology (SIR), the National Comprehensive Cancer Network (NCCN) the newly created Society of Interventional Oncology and the Radiological Society of Northern America (RSNA).